ECOG-ACRIN EA9171

A Phase II Study of adding the anti-PD-1 antibody pembrolizumab to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease

For more information about this clinical trial, click here

Schema & Eligibility ECOG-ACRIN EA9171

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO

Ask your physician about participating in this clinical trial or call us.